2025-10-04 - Analysis Report
Okay, here's an analysis of Intuitive Surgical (ISRG) based on the provided data.

**Report on Intuitive Surgical Inc. (ISRG)**

**1. Relative Performance vs. S&P 500 (VOO)**

*   **Ticker:** ISRG
*   **Company Overview:** Intuitive Surgical designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **ISRG Cumulative Return:** 68.50%
*   **VOO Cumulative Return:** 98.51%
*   **Spread:**
    *   Current: -33.5
    *   Max: 98.9
    *   Min: -35.1
    *   Relative Spread: 1.2
*   **Analysis:** ISRG has underperformed the S&P 500 significantly, with a cumulative return lagging by approximately 30.01%. The relative spread indicates that ISRG is near the bottom end of its historical performance range compared to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|--------|-------|------|--------|
| 2015-2017  | 68.0% | 77.6% | 40.0% | -0.1 | 43.6   |
| 2016-2018  | 64.0% | 72.2% | 49.0% | -0.0 | 57.2   |
| 2017-2019  | 54.0% | 72.2% | 31.0% | 0.2  | 70.6   |
| 2018-2020  | -6.0%  | 80.4% | -29.0% | 0.3  | 97.8   |
| 2019-2021  | 29.0% | 80.4% | -18.0% | 0.6  | 128.8  |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2  | 95.1   |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7  | 120.9  |
| 2022-2024  | 36.0% | 77.5% | 15.0%  | 1.7  | 187.1  |
| 2023-2025  | 31.0% | 72.7% | -32.0% | 0.8  | 162.2  |

*   **CAGR:** Fluctuates significantly, showing periods of high growth (68.0%) and declines (-23.0%).
*   **MDD:** Consistently high, indicating significant downside risk.
*   **Alpha:**  Mostly positive in the earlier periods, suggesting outperformance relative to its risk-adjusted benchmark.  However, it's been largely negative in recent periods, indicating underperformance.
*   **Beta:**  Low and even negative in the earlier periods suggesting ISRG has been historically less correlated to the market. More recently, beta has increased, showing a greater sensitivity to market movements.
*   **Cap(B):**  Demonstrates substantial growth in market capitalization over the period, although it has seen some fluctuations.

**2. Recent Price Movement**

*   **Current Price:** \$452.35
*   **Last Market:**
    *   Price: \$452.35
    *   Previous Close: \$443.01
    *   Change: 2.11%
*   **Moving Averages:**
    *   5-day MA: \$445.03
    *   20-day MA: \$445.65
    *   60-day MA: \$471.57
*   **Analysis:**  The stock is trading above its 5-day and 20-day moving averages but below its 60-day moving average. The 2.11% increase indicates recent positive momentum.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 64.61
*   **PPO:** 0.47
*   **Hybrid Signal:** Buy 100% of cash (2 shares - Very Safe - MRI:0.90). Monthly invest 0.8% of total investment ($1,000.00).
*   **Delta_Previous_Relative_Divergence:** -0.2 (Short-term decline)
*   **Expected Return:** 1046.1% (Long-term, relative to S&P 500)
*   **Analysis:** The MRI suggests a high investment recommendation. The RSI is approaching overbought territory. The PPO indicates positive momentum.  The negative relative divergence suggests potential short-term weakness. The substantial expected return indicates significant potential upside relative to the S&P 500 over the long term. The significant price change (2.11%) confirms the recent upside momentum.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Positive Coverage:** Several articles highlight positive aspects of ISRG, including outperforming market returns, bullish sentiment from Morgan Stanley, and broker recommendations to invest.
*   **Innovation:** The unveiling of AI-powered da Vinci 5 upgrades is a significant development, suggesting continued innovation and potential for future growth.
*   **Competition:** News about SS Innovations International's growth and cardiac telesurgery advancements suggests increasing competition in the surgical robotics space.

**4-2. Analyst Opinions**

*   **Consensus:**
    *   Key: Buy
    *   Mean: 1.94 (~Buy)
    *   Opinions: 27
    *   Target Price (avg/high/low): \$580.10 / \$685.00 / \$350.00
*   **Analysis:** Analyst consensus is generally positive, with a "Buy" rating and a significant average target price of \$580.10, implying substantial upside potential.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-07-23 | 1.84 | 2.44 B\$   |
| 2025-04-23 | 1.95 | 2.25 B\$   |
| 2024-10-18 | 1.59 | 2.04 B\$   |
| 2024-07-19 | 1.48 | 2.01 B\$   |
| 2025-07-23 | 1.48 | 2.01 B\$   |

*   **Analysis:** Revenue and EPS have generally been increasing over the past few quarters, indicating positive financial performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | \$2.44B    | 66.31%        |
| 2025-03-31 | \$2.25B    | 64.69%        |
| 2024-12-31 | \$2.41B    | 68.04%        |
| 2024-09-30 | \$2.04B    | 67.41%        |
| 2024-06-30 | \$2.01B    | 68.30%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-06-30 | \$17.85B   | 3.69%  |
| 2025-03-31 | \$17.11B   | 4.08%  |
| 2024-12-31 | \$16.43B   | 4.17%  |
| 2024-09-30 | \$15.58B   | 3.63%  |
| 2024-06-30 | \$14.71B   | 3.58%  |

*   **Analysis:** Revenue is increasing, and profit margins are consistently high. Equity is growing steadily, and ROE is relatively stable, suggesting good capital management and profitability.

**7. 종합 Analysis**

ISRG shows mixed signals. While it has underperformed the S&P 500 recently, there are positive indicators:

*   **Positive:** Recent price momentum, strong analyst ratings, continued revenue and earnings growth, high profit margins, and innovative product development (da Vinci 5).
*   **Concerns:** Underperformance relative to the S&P 500, potential short-term price weakness (Delta_Previous_Relative_Divergence), increasing competition, and relatively high Maximum Drawdown

**Investment Recommendation (Preliminary):**

Based on the MRI of 0.9 (High Investment Recommended) and the Hybrid Signal suggesting a "Buy" strategy, ISRG appears attractive for long-term investors. However, consider the underperformance relative to the S&P 500, potential short-term weakness, and the presence of competitors before making a final decision. The expected return of 1046.1% relative to the S&P 500 suggests a significant potential upside, assuming the company continues its growth trajectory.
